Shares of BioMarin Pharmaceutical (BMRN -9.90%) are up more than 40% in the last 12 months, and lately all eyes have been on its experimental Morquio syndrome drug. However, today the orphan drugmaker announced a $10 million deal to acquire Zacharon Pharmaceuticals. In this video, our health care analyst discusses this news and touches on last year's success of some prominent orphan drug companies, including NPS Pharmaceuticals (NASDAQ: NPSP) and Sarepta (SRPT 2.53%).